Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 09/12/2024

    Brain tumour cells rapidly integrate into brain-wide neuronal circuits

    Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumour-cells-rapidly-integrate-brain-wide-neuronal-circuits
  • Press release - 15/05/2026

    Heidelberg Collaborative Research Centre “Molecular Circuits of Heart Disease” secures second funding period

    The Collaborative Research Centre (CRC) 1550 “Molecular Circuits of Heart Disease” at Heidelberg University is entering its second funding period. The German Research Foundation (DFG) has approved approximately EUR 17.4 million in funding for the next four years. The spokesperson is Johannes Backs, Professor of Experimental Cardiology at the Heidelberg Faculty of Medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-collaborative-research-centre-molecular-circuits-heart-disease-secures-second-funding-period
  • Overview

    Basic research

    https://www.gesundheitsindustrie-bw.de/en/article/research
  • Dossier - 14/06/2016 Schematic showing the defence chain of a prokaryote with CRISPR/Cas - integration of a phage genome into the CRISPR array and an infection of another phage whose genome is already "known" in the array. The new piece of DNA is immediately destroyed by the CRISPR/Cas complex.

    CRISPR/Cas – genome editing is becoming increasingly popular

    The number of publications and patents that involve the CRISPR/Cas system has been increasing exponentially since the technique was first described a few years ago. The increase in funding for projects involving CRISPR/Cas also demonstrates how powerful this new method is. The targeted modification of genomes (also called gene or genome editing) using CRISPR/Cas is extraordinarily accurate and also has the potential to cure hereditary diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/crisprcas-genome-editing-is-becoming-increasingly-popular
  • Press release - 10/10/2025

    New tool offers single-cell study of specific genetic variants

    EMBL scientists created SDR-seq, a tool for single-cell DNA-RNA-sequencing that studies both DNA and RNA simultaneously, linking coding and non-coding genetic variants to gene expression in the same single cell.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-tool-offers-single-cell-study-specific-genetic-variants
  • Press release - 26/05/2026

    Heidelberg based development revolutionizes hepatitis D therapy worldwide: US Food and Drug Administration (FDA) approves hepatitis drug Hepcludex (bulevirtide)

    Joint press release of the Heidelberg Faculty of Medicine at Heidelberg University and the German Center for Infection Research: With the FDA approval of Hepcludex (bulevirtide), a therapy for chronic hepatitis D developed at the Heidelberg Faculty of Medicine at Heidelberg University, Heidelberg University Hospital, and the German Center for Infection Research (DZIF) has now reached the world’s most important pharmaceutical market.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-based-development-revolutionizes-hepatitis-d-therapy-worldwide-us-food-and-drug-administration-fda-approves-hepatitis
  • Press release - 18/06/2026

    Tailor-made functionalized gelatin – manufactured with reproducible results

    Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tailor-made-functionalized-gelatin-manufactured-reproducible-results
  • Press release - 18/11/2021

    Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system

    Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
  • Press release - 17/09/2024

    Five new cross-border doctoral networks at Universität Heidelberg

    Five transnational and cross-institutional doctoral networks at Heidelberg University are being funded as part of the “Marie Skłodowska-Curie Actions”. They work together on current scientific topics with high innovation potential. Ruperto Carola coordinates an MSCA Doctoral Network on artificial intelligence in physics, two networks in medicine, life sciences and engineering.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-new-cross-border-doctoral-networks-universitat-heidelberg
  • Press release - 03/09/2025

    Nature publication: Mechanical tensions as a driver of evolution

    When embryos grow, cells and tissue are constantly bumping into each other. This creates mechanical tensions that could endanger their development. A team from University of Hohenheim and the Japanese RIKEN Center have discovered that fly embryos have strategies to deal with this pressure. The different species have developed two different solutions. This ability to control mechanical tension could be a key to why so many body plans have evolved.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nature-publication-mechanical-tensions-driver-evolution
  • Dossier - 28/08/2018 Woman wearing a white lab coat in a laboratory looking at a tube she is holding in her hand.

    With molecular diagnostics to biomarker-based personalised therapy

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy

Page 12 / 12

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search